Eagle Pharmaceuticals, Inc.
EGRX · OTC
3/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $1 |
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | 84.6% | -8.7% | – |
| Gross Profit | – | $0 | $0 | $0 |
| % Margin | – | 70% | 75.4% | 75.8% |
| EBITDA | – | $0 | $0 | $0 |
| % Margin | – | 24.5% | 0.5% | 16% |
| Net Income | – | $0 | -$0 | $0 |
| % Margin | – | 11.3% | -5% | 6.4% |
| EPS Diluted | – | 2.73 | -0.66 | 0.87 |
| % Growth | – | 513.6% | -175.9% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |